Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc

ChainCatcher reminds readers to view blockchain rationally, enhance risk awareness, and be cautious of various virtual token issuances and speculations. All content on this site is solely market information or related party opinions, and does not constitute any form of investment advice. If you find sensitive information in the content, please click “Report”, and we will handle it promptly.